Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Skin biomarkers for atopic eczema therapy evaluation study 2
ISRCTN52806782Phase 2Completed
- Sponsor
- Sheffield Teaching Hospitals NHS Foundation Trust
- Start
- Nov 2022
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of crisaborole and betamethasone in atopic dermatitis (AD), sponsored by Sheffield Teaching Hospitals NHS Foundation Trust. Primary endpoint: Change in epidermal thickness on the volar forearm. Started Nov 2022; status: completed.
02
Drugs
crisaborolebetamethasone
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on ISRCTN52806782.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN52806782.